Bowel preparation quality scales for colonoscopy
- PMID: 30018478
- PMCID: PMC6048432
- DOI: 10.3748/wjg.v24.i26.2833
Bowel preparation quality scales for colonoscopy
Abstract
Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer-related death in the United States. Colonoscopy is widely preferred for CRC screening and is the most commonly used method in the United States. Adequate bowel preparation is essential for successful colonoscopy CRC screening. However, up to one-quarter of colonoscopies are associated with inadequate bowel preparation, which may result in reduced polyp and adenoma detection rates, unsuccessful screens, and an increased likelihood of repeat procedure. In addition, standardized criteria and assessment scales for bowel preparation quality are lacking. While several bowel preparation quality scales are referred to in the literature, these differ greatly in grading methodology and categorization criteria. Published reliability and validity data are available for five bowel preparation quality assessment scales, which vary in several key attributes. However, clinicians and researchers continue to use a variety of bowel preparation quality measures, including nonvalidated scales, leading to potential confusion and difficulty when comparing quality results among clinicians and across clinical trials. Optimal clinical criteria for bowel preparation quality remain controversial. The use of validated bowel preparation quality scales with stringent but simple scoring criteria would help clarify clinical trial data as well as the performance of colonoscopy in clinical practice related to quality measurements.
Keywords: Aronchick scale; Boston Bowel Preparation Scale; Bowel preparation; Colonoscopy; Ottawa Bowel Preparation Scale.
Conflict of interest statement
Conflict-of-interest statement: David Kastenberg has received research support from and served as a consultant for Medtronic, and is on the advisory boards of Ferring Pharmaceuticals Inc. and Salix Pharmaceuticals. Gerald Bertiger has served as a consultant and has been a part of the speakers bureau for Ferring Pharmaceuticals Inc. Stuart Brogadir is an employee of Ferring Pharmaceuticals Inc. Editorial support was provided by The Curry Rockefeller Group, LLC, which was funded by Ferring Pharmaceuticals.
Figures


References
-
- Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193. - PubMed
-
- US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564–2575. - PubMed
-
- Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56:143–159; quiz 184-185. - PubMed
-
- Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM, Wender RC. Screening for colorectal cancer and evolving issues for physicians and patients: a review. JAMA. 2016;316:2135–2145. - PubMed
-
- U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–637. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical